Aptose Biosciences Inc. Files 8-K
Ticker: APTOF · Form: 8-K · Filed: Apr 26, 2024 · CIK: 882361
Sentiment: neutral
Topics: material-agreement, equity-sale, corporate-action
Related Tickers: APTO
TL;DR
APTO filed an 8-K on 4/24 detailing material agreements and equity sales.
AI Summary
On April 24, 2024, Aptose Biosciences Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and other events. This filing is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Why It Matters
This 8-K filing indicates significant corporate actions by Aptose Biosciences Inc., including definitive agreements and equity sales, which could impact its financial standing and future operations.
Risk Assessment
Risk Level: medium — 8-K filings often contain material information that can lead to stock price volatility, especially those related to definitive agreements and equity sales.
Key Players & Entities
- Aptose Biosciences Inc. (company) — Registrant
- April 24, 2024 (date) — Date of earliest event reported
- 20240424 (date) — Conformed period of report
- 0001171843-24-002270 (accession_number) — Filing accession number
FAQ
What specific material definitive agreement did Aptose Biosciences Inc. enter into on April 24, 2024?
The filing states that Aptose Biosciences Inc. entered into a material definitive agreement on April 24, 2024, but the specific details of this agreement are not provided in the provided text.
What was the purpose of filing this 8-K report?
This 8-K report was filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 to report on the entry into a material definitive agreement, unregistered sales of equity securities, and other events.
Has Aptose Biosciences Inc. undergone any name changes previously?
Yes, Aptose Biosciences Inc. was formerly known as LORUS THERAPEUTICS INC. and prior to that, IMUTEC PHARMA INC.
What is the Standard Industrial Classification (SIC) code for Aptose Biosciences Inc.?
The SIC code for Aptose Biosciences Inc. is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Where is Aptose Biosciences Inc. headquartered?
Aptose Biosciences Inc. is headquartered in Toronto, Canada, with its business and mailing address at 251 CONSUMERS ROAD, SUITE 1105, TORONTO, A6, M2J 4R3.
Filing Stats: 912 words · 4 min read · ~3 pages · Grade level 10.3 · Accepted 2024-04-26 07:30:12
Key Financial Figures
- $1.71 — 39,181 warrants at an exercise price of $1.71 per common share. Each warrant will be
Filing Documents
- f8k_042624.htm (8-K) — 29KB
- exh_41.htm (EX-4.1) — 94KB
- 0001171843-24-002270.txt ( ) — 319KB
- apto-20240424.xsd (EX-101.SCH) — 3KB
- apto-20240424_lab.xml (EX-101.LAB) — 33KB
- apto-20240424_pre.xml (EX-101.PRE) — 22KB
- f8k_042624_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events On April 25, 2024, the Company received a letter (the " April Letter ") from the Listing Qualifications Department (the " Staff ") of Nasdaq notifying the Company of the Staff's determination that the Company has regained compliance with Nasdaq Listing Rule 5635(d). As previously reported in the Company's Current Report on Form 8-K filed on March 1, 2024, the Company received a letter on February 29, 2024 from the Staff notifying the Company that it had violated Listing Rule 5635(d) because the Company did not obtain shareholder approval for the Hanmi Transaction. Nasdaq stated that completion of the Hanmi Transaction involved the issuance of greater than 20% of the issued and outstanding common shares of the Company at a discount to the Nasdaq official closing price on January 25, 2024, the date of the subscription agreement between the Company and Hanmi. In its April Letter, the Staff stated that it has determined that the Company has regained compliance with Listing Rule 5635(d) as a result of the Amended Warrant Agreement. Accordingly, the Staff has determined that the matter is now closed. Item9.01.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Description 4.1 Amended Warrant Agreement 104 Cover Page Interactive Data File (formatted as inline XBRL) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aptose Biosciences Inc. Date: April 26, 2024 By: /s/ William G. Rice, Ph.D. William G. Rice, Ph.D. Chairman, President, and Chief Executive Officer